Home

RORY B RIGGS

CIK 1016835 · Chief Executive Officer · last filed 2026-06-04

RORY B RIGGS is a Chief Executive Officer who has filed 121 SEC Form 4 insider transactions across 4 companies since 2014. The most recent filing, for CBUS, was dated Jun 4, 2026. Across all open-market trades the lifetime net is −$221.9M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $49.7M across reported positions.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure

$49.68M

Companies

4

Total Filings

121

Lifetime Open-Market Net

-$221.94M

Filer Profile

Reported Address
65 RAILROAD AVE
RIDGEFIELD, NJ 07657
Profile details as reported on the filer's SEC submissions — for individual insiders the address is often in care of the issuer. Related filers are identified from jointly filed SEC submissions and shared reported addresses. View filings on SEC EDGAR.

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
CBUS Director 14,940,447 $1.59 $23.76M $5.47M 12 2026-06-04
Intra-Cellular Therapies, Inc. (ITCI) Delisted Director 0 $131.87 $0 -$12.95M 64 2025-04-02
RPRX Director 405,286 $63.96 $25.92M -$208.34M 27 2024-02-22
KYNTRA BIO, INC. (FGEN) Delisted Director 40,059 $9.75 $390.6K -$6.13M 15 2021-05-28

Recent Filings

121 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
Filed Symbol Action Net Shares Net $ Link
2026-06-04 CBUS Grant (A) — $0 EDGAR
2026-02-02 CBUS Grant (A) +333,333 $500.0K EDGAR
2025-06-11 CBUS Exer (X) +4,050,000 $900 EDGAR
2025-06-10 CBUS Grant (A) +5,714,286 $10.00M EDGAR
2025-05-27 CBUS Grant (A) — $0 EDGAR
2025-04-02 Intra-Cellular Therapies, Inc. (ITCI) Delisted Disp (D) −131,512 -$17.36M EDGAR
2025-01-23 CBUS Grant (A) — $0 EDGAR
2025-01-10 CBUS Conv (C) — $0 EDGAR
2025-01-03 Intra-Cellular Therapies, Inc. (ITCI) Delisted Grant (A) +215 $18.0K EDGAR
2024-10-15 Intra-Cellular Therapies, Inc. (ITCI) Delisted Exer (M) +14,189 $0 EDGAR
Showing 1–10 of 121
Page 1 of 13
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.